Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.26, $0.04 better than the analyst estimate of $0.22. Revenue for the quarter came in at $271.6 million versus the consensus estimate of $259.74 million.

Full-Year 2017 Guidance

The Company increased its full-year 2017 guidance net sales range to $1.030 billion to $1.050 from the previous range of $1.010 billion to $1.045 billion and increased the lower end of its full-year 2017 adjusted EBITDA guidance to $350 million, resulting in an adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million.

Highlights

• Third-Quarter 2017 Net Sales of $271.6 Million
• Third-Quarter 2017 Net Loss of $64.0 Million; Adjusted EBITDA of $108.1 Million
• Third-Quarter 2017 GAAP Operating Cash Flow of $68.3 Million; Non-GAAP Operating Cash Flow of $83.5 Million
• Third-Quarter 2017 Net Sales of Rare Disease Medicines Represented 59 Percent of Net Sales and Increased 65 Percent from Third-Quarter 2016
• On Oct. 25, 2017, Announced Enrollment in the Phase 3 Clinical Trial Evaluating Teprotumumab for Thyroid Eye Disease
• Increasing Full-Year 2017 Net Sales Guidance Range to $1.030 Billion to $1.050 Billion; Increasing Lower End of Full-Year 2017 Adjusted EBITDA Guidance, Resulting in Adjusted EBITDA Guidance Range of $350 Million to $375 Million
• Providing KRYSTEXXA® 2018 Net Sales Guidance of More than 50 Percent Year-Over-Year Growth

GUIDANCE:

Horizon Pharma sees FY2017 revenue of $1.03-1.05 million, versus the consensus of $1.04 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.